Monitor **Deloitte.**






Future of business interactions

MedTech Forum

January 24, 2018


The daily struggle of business interactions

In every day operations, business interactions cause




Major pain points throughout the QtC process

Customer experience suffers at each step of the QtC process including interaction with large field forces and processing in shared service centers



Major pain points throughout the QtC process

Study participants share common perspective on major issues; providers often question the value of sales force; industry faces incorrect master data as dominant issue



Potential to improve top line and bottom line impact

Study revealed, improving business interactions could lead to a revenue upside of up to 20% and an estimated 25% SG&A savings

Improving business interactions yields the potential of...

Revenue growth via increased share of wallet of up to



"By 2020 we aim to generate 30% of our revenue via our remote sales channel." 1)

- Moving from classic sales approach (e.g. more sales reps, more products) to innovative sales models (e.g. remote sales and services) with the objective to improve Cx
- Provide differentiated services aligned with providers' demand (e.g. remote training and education, inventory management concept with transparency on total cost of ownership)
- Acting as partner (provider and industry) on the basis of transparency and trust

Note: 1) EMEA Business Unit Head; 2) EMEA Operations Director



SG&A savings of up to



25%

"We can save **20% in costs**by 2020 through systemizing tender management." ²⁾

- Harmonized and aligned data structures and master data using a single, online platform/ pool for exchange will lead to fewer error rates through increased transparency and simplification
- Reduced workload and increased customer satisfaction through improved order-to-cash process efficiency and a more electronically managed transactions
- Reduced organizational complexity through better integration of sales force and its sizing

Combining customer experience with digital interaction models

In B2C, we have seen how focus on customer experience and digital interaction models can drive success

Why we love them...



amazon

Key items of good customer experience and interactions

- Online portfolio with descriptions and prices
- · Easy to use platform to navigate
- Real-time delivery status and history
- Algorithms that suggest alternative products



Key items of good customer experience and interactions

- Broad transportation coverage in metropolitan areas
- Offering best price through tendering, yet customer segment specific
- Fully electronic order and payment system



Keyitems of good customer experience and interactions

- State of the art and innovative products
 - Letting customers chose the channel: Apple store or online
 - Superior customer services and warranty have a price, but drive customer loyalty

2018

Current efforts in the healthcare sector

Players in the healthcare sector are piloting to improve customer experience and business interactions, but efforts remain siloed



MedTech industry



Improving customer experience through inventory management solution that is easy to use and allows real-time monitoring (e.g., consignment stocks)



ROESER

Providers

By managing interactions with MedTech companies, Roeser significantly simplifies procurement for Sana hospitals



Public sector & organizations



Estonia

Introduction of procurement platforms for medicinal products to improve customer experience in procurement process









Improving efficiency of interactions by connecting data and standardizing pricing




Creating a better customer experience through price transparency, open book contracts, consolidated invoicing, and IT integration

Expected savings of €700m

Source: GE Healthcare, press release; CardinalHealth website; Sana Kliniken AG, press release; NHS webside; MedTech Europe, MEAT and value-based procurement, Event Report, March 2016

Digital maturity amongst players
While MedTech companies are more open to digitalization than providers, it is still uncertain who will drive change in this field



Preconditions for higher level of digitalization

The industry has not yet build the IT infrastructure, committed the investment and established the partnerships that are necessary to move to digital business interactions



Common IT and data standards required, but not yet in Nace for MedTech and providers



Providers, GROs, and MedTech companies in Germany agreed on eCl@ss standard, but not pet implemented


Enables ord
but no data



Enables order automation, but no data synchronization



Enables electronic exchange of document, but limited adoption in industry




Note: Based on interview results

Key barriers for improvement

Both industry and providers in Europe are willing to improve business interactions but face substantial barriers

Major barriers to improvements, rated by the interview partners are...




- To some extend, management focus has to shift from topline to efficient business interactions
- · Talent and skills need to be developed on local, regional and global level
- Investments require careful planning and evaluation 3

- Evaluation of cost sharing models to be considered

 Partnerships on dialettechnology technology development may be planned with multiple stakeholders


Note: Regulatory challenges and missing support from industry/ provider side were considered not to be among the top 3 barriers, (1) % of interviewees who ranked the barriers accordingly

Summary
Business interactions can be improved through enhanced customer experience and digitalization to secure profitably growth for all stakeholders



Future of Business Interaction Scenarios

Building on our study results, we went into a scenario process to go beyond short-/mid-term impact and identify what is relevant for MedTech by 2030



Future of Business Interaction Scenarios | Implications

... each scenario has distinct implications for Medtech players, hospitals and GPOs

Total cost of ownership across all transactions **Patchwork** Knocking on heaven's door xe[©]GPOS **GPOS** Hospitals Medtechs Hospitals Medtechs · Building company reduction of SG&A, Partnership with Extension of service Increased M&A Extension of service · Partnerships drive Substantial business specific, value driven activities to vertically portfolio towards efficient transactions solutions & integrate value chain data-based offerings Customized · Topline growth and Optimization of · Increase quality of Empowered to better treatments improve individual business patient care at higher connect hospitals with patient care quality Partnership with 0 model at reasonable merchants cost ecosystem Diverse set of data 🚫 One set of data Existence of common data standards & transaction standards & transaction standards transaction platforms platforms operated by platforms operated by multiple parties 3rd parties **Paralysis** unistic provider world Hospitals Medtechs **GPOS** Hospitals Medtechs **GPOS** · Increased pressive · Focus on pure cost Increased cost Transactional No advancements as Increased cost of power relationship they only rely on their and the reduction of competition drives pressure cutting environment own data value add services M&A · Reduced application Have low commitment · Quality issues lead to of value add services Optimization of Low entry barriers and lack of adjacent higher cost of create opportunities business models at services high costs while ownership for new players innovation lacks Net price per product

Uncertainty remains

We want your participation in the future process towards better business interactions

Today

The MedTech Forum

Uncertainty remains red ledit

- Who will drive to ture change? MedTech or providers?
- Which role will GPOs play?
- · Will regulation be a enabler or barrier?

Define future scenarios

- What are drivers of future change?
- What are possible scenarios?
- Which scenarios do you think are most likely?

for the long view

- w will companies be impacted?

 Who will profit from the scenarios?

 will MedTech exestive and? How will MedTech companies respond?

 All MedTech companies

Align on annual update

- · Are you interested in annual
- · What content would most
- participate in interviews?

Monitor Deloitte.

This presentation was been solely prepared for the client in accordance with the agreed engagement letter. The presentation shall be treated as confidential. Any disclosure to third parties requires our prior express written consent, except to the extent such disclosure by the client is require by law. Unless otherwise expressly agreed in writing, no person other than the client is entitled to place reliance on the presentation or to derive confidential. Any disclosure to third parties requires our prior express written consent, except to the extent such disclosure by the client is required by law. Unless otherwise expressly agreed in writing, no person other than the client is entitled to place reliance on the presentation or to derive any rights from the presentation. The maximum liability amount agreed with the client shall be owed altogether only once; as such the client and any third parties are joint and several creditors (Gesamtgläubiger). The presentation has been prepared on the basis of the intermediate provided by the client, unless otherwise agreed with the client we have not verified such information as to its accuracy and completeness.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTLS, its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL and each of its member firms are legally separate and independent entities. "Deloitte Global") does not provide services to clients. Please see www.deloitte.com/de/UeberUns for a more detailed description of DTTL and its member firms.

Deloitte provides audit, risk advisory, tax, financial advisory and consulting services to public and private client's spanning multiple industries; legal advisory services in Germany are provided by Deloitte Legal. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte's approximately 263,900 professionals are committed to making an impact that matters.

pendix The Medich Fourth Millers reserved. Technological in Market and Information of the Medical Fourth Millers reserved.

Who we are – Deloitte in Life Sciences and Healthcare

Deloitte serves more than 87% of the Fortune Global 500 Life Sciences and Healthcare companies

Life Sciences

- 100% of the Top 10 Global Pharma companies (Fierce Pharma)
- 100% of the Top 10 Global MedTech Manufacturers (MPO Magazine)
- 100% of the Top 10 Global Biotechol's companies (Forbes)
- 100% of the Top 10 Global Generic companies (Fierce Pharma)

Oealth Plans

- 95% of the top 20 U.S. health plans
- 50% of the top 10 Blue Cross Blue Shield Plans (AISHealth)
- 65% of the 20 largest provider sponsored plans (Healthcare Finance)

Providers

- 75% of the Best Hospitals Honor Roll (U.S. News)
- 9 of the 10 largest health care systems (Modern Healthcare)
- 6 of the 10 largest for-profit healthcare systems (Modern Healthcare)
- 90% of the 10 largest secular notfor-profit healthcare systems (Modern Healthcare)
- 90% of the 10 largest Catholic Health Systems (Modern Healthcare)
- 80% of the largest non-Catholic Health Systems (Modern Healthcare)
- 6 out of 10 Best Children's Hospitals Honor Roll (U.S. News)

Federal Health

- All major Federal Health
 Organizations, including CMS, HOS,
 CDC, CMS, FDA, NIH, and VA.
- Major health related non-profits including PCORI, CCFA, Rr. Susan Love Research Foundation, Bill and Melinda Gates Foundation, Michael J. Fox Foundation, and the American Cancel Society

Consistent performance and growth:


Numerous third party accolades citing Deloitte as a leader in LSHC market:

- Deloitte is the largest Life Sciences consulting organization in the world (2016)
- Deloitte ranked #3 by Vault for best consulting firms for health care consulting (2016 ranking)
- Deloitte Consulting named a global leader in Private Healthcare Consulting by Kennedy (2014)
- Deloitte ranked #1 globally in Healthcare Risk Consulting based on revenue and capabilities (8) Kennedy (2014)
- Deloitte named a global leader in Life Sciences Industry Consulting by Kennedy (2014)


Source: Fierce Pharma, MPO Magazine, Forbes, AIS Health, Healthcare Finance, U.S. News, Modern Healthcare, Vault, Kennedy

Who we are - Deloitte's global Life Sciences and Healthcare scope

We have ~12,600 dedicated Life Sciences and Healthcare specialists in 90 countries



CLV and scenario design overview
The Center for the Longview as part of Deloitte offers a powerful tool to create scenarios for future states



Contacts





Michael Dohrmann edech Forum.

ead of the Deloitte New of P Center of Practice for MedTech

Michael has 10 years of consulting experience in MedTech. Prior he spend 10 years working in the MedTech industry

mdohrmann@deloitte.de

Florian Klein

Lead of the German Center for the Longview

Florian founded and leads the Center for the Long View (CLV), which is Deloitte's global center of excellence for scenario planning

fklein@deloitte.de

Koen Segers

Director in Life Sciences and Healthcare

Supported by a scientific background Koen build his expertise in the Life Sciences industry and was 25 years of hands-on experience

kose Mers@deloitte.com

Georg Selle

Senior Manager in Life Sciences and Healthcare

Georg is a Medical Engineer by training. He has done strategic consulting projects for the past 6 years

gselle@deloitte.de